How cost effective is the Symplicity radio frequency procedure in the UK?
Sharing knowledge of renal denervation (RDN) as a new device-based therapy for control of raised blood pressure
Dr Sharp qualified from Edinburgh Medical School in 1998. He was appointed as a Consultant Cardiologist at the Royal...
Dr Sharp qualified from Edinburgh Medical School in 1998. He was appointed as a Consultant Cardiologist at the Royal Devon and Exeter Hospital in 2011, before moving to the University Hospital of Wales, in Cardiff, UK in the summer of 2019, where he is now Honorary Professor of Cardiology. He conducted his early training at the Royal Infirmary of Edinburgh, before moving to London for his senior clinical training. He completed the Milan-Imperial Interventional Cardiology Fellowship programme, having spent a year in San Raffaele and Columbus Hospitals, Milan, Italy, under the tutelage of Professor Antonio Colombo. He also spent three years training in interventional cardiology at St Mary’s Hospital and The Hammersmith Hospital (Imperial College Hospitals) in London. Prof Sharp was awarded an MD postgraduate research degree from the University of Edinburgh for his work on the hypertensive heart and leads a large research programme in Wales. He has an international reputation for leading the development of device-based treatments for hypertension (in particular that of renal denervation) and pulmonary embolism, as well as the advancement of intracoronary imaging and physiology.
Professor Felix Mahfoud is an Associate Professor and senior physician of Internal Medicine and Cardiology at...
Professor Felix Mahfoud is an Associate Professor and senior physician of Internal Medicine and Cardiology at Saarland University Hospital, and Affiliate/Visiting Professor Harvard-MIT Biomedical Engineering, Institute of Medical Engineering and Science, Cambridge, US. Professor Mahfoud completed training in Cardiology and Interventional Cardiology at the Department for Internal Medicine III, Saarland University Hospital, Germany in 2014. Since 2017, he has served as Vice Chairman of the ‘Working Group on Interventional Hypertension Treatment’ for the European Society of Hypertension, and as a Committee Member of the 2018 Hypertension Guidelines.